AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31793472 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish Music Perception Test (MPT)
Number of subjects: 100
Study 28383400 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily (except on dialysis days)
Number of subjects: 100
Study 28383400 — intervention group
Group type: COMPARATOR
Intervention: Standard non-RAAS antihypertensive agents
Number of subjects: 100
Study 25489763 — intervention group
Group type: EXPERIMENTAL
Intervention: Left double-lumen tracheal tubes without a hook
Number of subjects: 184
Study 25489763 — intervention group
Group type: COMPARATOR
Intervention: Left double-lumen tracheal tubes with a hook
Number of subjects: 184
Study 24078335 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (DHD)
Number of subjects: 245
Study 24078335 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (C)
Number of subjects: 245
Study 22492936 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive acceleration stimulus applied to the mastoid
Number of subjects: 13
Study 22492936 — intervention group
Group type: COMPARATOR
Intervention: Galvanic stimulation (GVS)
Number of subjects: 13
Study 22492936 — intervention group
Group type: COMPARATOR
Intervention: 500-Hz vibration
Number of subjects: 13
Study 22492936 — intervention group
Group type: COMPARATOR
Intervention: Seated position during stimulation
Number of subjects: 13
Study 19204301 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 10101
Study 19204301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study 17276267 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic IOL with haptic angulation (ACR6D SE, Laboratoires Cornéal)
Number of subjects: 52
Study 17276267 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic acrylic IOL without haptic angulation (C-flex 570C, Rayner)
Number of subjects: 52
Study 17276267 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both IOL groups
Number of subjects: 52
Study 15045504 — intervention group
Group type: EXPERIMENTAL
Intervention: Running sprints
Number of subjects: 25
Study 15045504 — intervention group
Group type: COMPARATOR
Intervention: Cycling sprints
Number of subjects: 25
Study 15045504 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated sprints
Number of subjects: 25
Study 12654211 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 26
Study 12654211 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 26
Study 9034263 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (loading dose administered)
Number of subjects: 322
Study 8094392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 8094392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX; 8 mg, orally)
Number of subjects: 10
Study 8094392 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PRO; 40 mg, orally) after DEX
Number of subjects: 10
Study 8094392 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO; 0.300 mg, orally) after DEX
Number of subjects: 10
Study 8094392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD; 120 mg, orally) after DEX
Number of subjects: 10
Study 8094392 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PRO)
Number of subjects: 10
Study 8094392 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO)
Number of subjects: 10
Study 8094392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD)
Number of subjects: 10
Study 3298088 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate-rich feeding (L)
Number of subjects: 8
Study 3298088 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid carbohydrate-rich feeding (S)
Number of subjects: 8
Study 3298088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum solid food consumption (AL)
Number of subjects: 8
Study 30295914 — intervention group
Group type: EXPERIMENTAL
Intervention: Session-introducing intervention with mindfulness elements (SIIME)
Number of subjects: 162
Study 30295914 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 162
Study 30295914 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 162
Study 28791787 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:2 diet (two non-consecutive days of 2460 KJ (600 calories) and 5 days of ad libitum eating per week)
Number of subjects: 24
Study 28791787 — intervention group
Group type: COMPARATOR
Intervention: Standard energy-restricted diet (SERD) (2050 KJ (500 calorie) reduction per day)
Number of subjects: 24
Study 27317044 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice and referral to external AOD services
Number of subjects: 0
Study 27317044 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25293480 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 60
Study 25293480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BIS monitoring)
Number of subjects: 60
Study 22832260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent rLP2086 vaccine (60, 120, or 200 μg)
Number of subjects: 48
Study 22832260 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 22832260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent rLP2086 vaccine
Number of subjects: 48
Study 20226843 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stress (high intensity exercise, 12 min, 70-85% HR max, n=19)
Number of subjects: 40
Study 20226843 — intervention group
Group type: COMPARATOR
Intervention: Cognitive stress (Letter Digit Span and d2-test, n=21)
Number of subjects: 40
Study 18065368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional steroid
Number of subjects: 24
Study 18065368 — intervention group
Group type: COMPARATOR
Intervention: Silicone gel sheeting
Number of subjects: 24
Study 16094554 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program (duration: 6 months)
Number of subjects: 117
Study 12948311 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% piroxicam ophthalmic solution
Number of subjects: 40
Study 12948311 — intervention group
Group type: COMPARATOR
Intervention: 0.1% diclofenac sodium ophthalmic solution
Number of subjects: 40
Study 10982578 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclipse
Number of subjects: 50
Study 10982578 — intervention group
Group type: COMPARATOR
Intervention: Nicotrol inhaler
Number of subjects: 50
Study 8831918 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ciprofibrate/day
Number of subjects: 18
Study 8831918 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ciprofibrate/day
Number of subjects: 18
Study 8831918 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate HB/day
Number of subjects: 18
Study 1403397 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 0.25 mg/kg per dose, every 8 hours for a total of three doses
Number of subjects: 50
Study 1403397 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 50
Study 4059871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin injections every 8 hours (TID) for 4 days followed by every 12 hours (BID)
Number of subjects: 11
Study 4059871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin injections every 12 hours (BID) for 4 days followed by every 8 hours (TID)
Number of subjects: 11
Study 2979067 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate, 5 to 10 mg IV
Number of subjects: 30
Study 2979067 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine, 25 to 50 mg IV
Number of subjects: 30
Study 2979067 — intervention group
Group type: EXPERIMENTAL
Intervention: Shivering (graded 0 to 4)
Number of subjects: 30
Study 30866981 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive team‐based intervention including practice facilitation, workflow mapping, practice improvement model, education for patients, and community partnership for social marketing campaign
Number of subjects: 40
Study 27888575 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (2 g infusion)
Number of subjects: 60
Study 27888575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study 25500574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (0.3 mg/kg)
Number of subjects: 100
Study 25500574 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam (0.5 mg/kg)
Number of subjects: 100
Study 23040523 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (0 IU, 15 IU, 60 IU, or 125 IU) SC every other day
Number of subjects: 37
Study 23040523 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g T gel daily (75 mg delivered)
Number of subjects: 37
Study 23040523 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist acyline
Number of subjects: 37
Study 23040523 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 IU hCG)
Number of subjects: 37
Study 21455729 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) with up to five individual counselling sessions in 1 year, in addition to usual care
Number of subjects: 349
Study 21455729 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 349
Study 19087606 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao capsules (prophylactic oral administration for 3 days before operation)
Number of subjects: 87
Study 19087606 — intervention group
Group type: COMPARATOR
Intervention: Control (no Yunnan Baiyao administration)
Number of subjects: 87
Study 16491236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblasts from primary pterygia
Number of subjects: 43
Study 16491236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblasts from recurrent pterygia
Number of subjects: 43
Study 16491236 — intervention group
Group type: COMPARATOR
Intervention: Fibroblasts from normal Tenon capsule
Number of subjects: 43
Study 16491236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleshy and involutive pterygia
Number of subjects: 43
Study 16491236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygia of Grades I‐II and III‐IV
Number of subjects: 43
Study 15312097 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque control program
Number of subjects: 555
Study 15312097 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinued after 6 years)
Number of subjects: 555
Study 10686207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 362
Study 10686207 — intervention group
Group type: COMPARATOR
Intervention: Clinical touch embryo transfer
Number of subjects: 362
Study 9356856 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionormalizer (BN) 9g by mouth every night for one week
Number of subjects: 46
Study 9356856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 8469324 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 64
Study 8469324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 3511933 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (50 mg for 10 days)
Number of subjects: 29
Study 3511933 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumecinol (200 mg and 600 mg for 6 days)
Number of subjects: 29
Study 3511933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (600 mg for 6 days)
Number of subjects: 29
Study 3511933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29377186 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders of the stereotype about women's communality
Number of subjects: 202
Study 29377186 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders of the stereotype about men's agency
Number of subjects: 202
Study 29377186 — intervention group
Group type: COMPARATOR
Intervention: Control/no-stereotype condition
Number of subjects: 202
Study 27439969 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal colonic acetate infusion (180 mmol/l)
Number of subjects: 6
Study 27439969 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal colonic acetate infusion (100 mmol/l)
Number of subjects: 6
Study 27439969 — intervention group
Group type: COMPARATOR
Intervention: Proximal colonic acetate infusion
Number of subjects: 6
Study 27439969 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 24893832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 100mg/day for 4.5 days
Number of subjects: 35
Study 23672224 — intervention group
Group type: EXPERIMENTAL
Intervention: Western drugs
Number of subjects: 9061
Study 23672224 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine
Number of subjects: 9061
Study 23672224 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 9061
Study 20518763 — intervention group
Group type: EXPERIMENTAL
Intervention: TURis‐PVP
Number of subjects: 155
Study 20518763 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 155
Study 18271842 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mid-dilution hemodiafiltration (HDF-MD)
Number of subjects: 8
Study 18271842 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis (HF-HD)
Number of subjects: 8
Study 15693603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture on two implants (IMP-group)
Number of subjects: 149
Study 15693603 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete dentures (VP-group)
Number of subjects: 149
Study 15693603 — intervention group
Group type: COMPARATOR
Intervention: Complete denture after preprosthetic surgery (MVP-group)
Number of subjects: 149
Study 30220293 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed generic formulation of abiraterone acetate (250 mg)
Number of subjects: 80
Study 30220293 — intervention group
Group type: COMPARATOR
Intervention: Branded formulation of abiraterone acetate (Zytiga, 250 mg)
Number of subjects: 80
Study 30220293 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 80
Study 10518263 — intervention group
Group type: EXPERIMENTAL
Intervention: Free smoke alarms and fire safety information distributed by community groups and paid workers.
Number of subjects: 160000
Study 7675718 — intervention group
Group type: EXPERIMENTAL
Intervention: Long arm plaster immobilization
Number of subjects: 31
Study 7675718 — intervention group
Group type: EXPERIMENTAL
Intervention: Short arm plaster immobilization
Number of subjects: 31
Study 7675718 — intervention group
Group type: COMPARATOR
Intervention: Ace Wrap bandage
Number of subjects: 31
Study 2405727 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine antimonate (Glucantime), 850 mg antimony/day im for 15 days
Number of subjects: 66
Study 2405727 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized controlled heat, 50 degrees C for 30 sec, 3 treatments at 7 day intervals
Number of subjects: 66
Study 2405727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 6990946 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam every six hours for 48 hours
Number of subjects: 131
Study 6990946 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 131
Study 28799030 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instruction (VI)
Number of subjects: 40
Study 28799030 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus (EF)
Number of subjects: 40
Study 28799030 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 40
Study 26476086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (SBP <120 mm Hg)
Number of subjects: 3087
Study 26476086 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure lowering (SBP <140 mm Hg)
Number of subjects: 3087
Study 26476086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 3087
Study 24872892 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month multicomponent obesity prevention intervention
Number of subjects: 1474
Study 24872892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1474
Study 22742578 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 4000 mg q.d.s.
Number of subjects: 60
Study 22742578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg q.d.s.
Number of subjects: 60
Study 22742578 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 4000 mg q.d.s. and Aspirin 325 mg q.d.s.
Number of subjects: 60
Study 20378868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate infusion
Number of subjects: 327
Study 20378868 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 327
Study 17356283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for comorbid anxiety disorder
Number of subjects: 34
Study 17356283 — intervention group
Group type: COMPARATOR
Intervention: Alcohol treatment alone
Number of subjects: 34
Study 16323384 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS over the acupuncture points plus infrared irradiation
Number of subjects: 218
Study 16323384 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training plus infrared irradiation
Number of subjects: 218
Study 16323384 — intervention group
Group type: COMPARATOR
Intervention: Infrared irradiation alone
Number of subjects: 218
Study 12510991 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 18
Study 12510991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9832573 — intervention group
Group type: EXPERIMENTAL
Intervention: Handled infants (n = 21)
Number of subjects: 48
Study 9832573 — intervention group
Group type: COMPARATOR
Intervention: Nonhandled infants (n = 27)
Number of subjects: 48
Study 7865625 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumour-associated glycoprotein 72 antibody B72.3
Number of subjects: 0
Study 7865625 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific murine immunoglobulins
Number of subjects: 0
Study 7865625 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat extraction of serum samples
Number of subjects: 0
Study 2724027 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC containing paste
Number of subjects: 36
Study 2724027 — intervention group
Group type: COMPARATOR
Intervention: Placebo paste
Number of subjects: 36
Study 29659438 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB)
Number of subjects: 100
Study 29659438 — intervention group
Group type: COMPARATOR
Intervention: Suprascapular-axillary nerve block (SSB)
Number of subjects: 100
Study 27829410 — intervention group
Group type: EXPERIMENTAL
Intervention: Active catgut implantation at acupoints (two sessions, once every two weeks)
Number of subjects: 0
Study 27829410 — intervention group
Group type: COMPARATOR
Intervention: Sham catgut implantation at acupoints (two sessions, once every two weeks)
Number of subjects: 0
Study 27829410 — intervention group
Group type: EXPERIMENTAL
Intervention: Active catgut implantation at acupoints
Number of subjects: 0
Study 27829410 — intervention group
Group type: COMPARATOR
Intervention: Sham catgut implantation at acupoints
Number of subjects: 0
Study 24829088 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml glucose drink (200 kcal)
Number of subjects: 10
Study 24829088 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion at 4 kcal/min into the proximal Roux-limb
Number of subjects: 10
Study 24829088 — intervention group
Group type: COMPARATOR
Intervention: 4 kcal/min duodenal infusion (control group)
Number of subjects: 10
Study 22689678 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐consolidation immunotherapy with histamine dihydrochloride and interleukin‐2
Number of subjects: 145
Study 22689678 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride
Number of subjects: 145
Study 22689678 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine H(2) receptor expression
Number of subjects: 145
Study 20300027 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVG)
Number of subjects: 18
Study 20300027 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 18
Study 18853933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg (GBX15)
Number of subjects: 794
Study 18853933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg (GBX10)
Number of subjects: 794
Study 18853933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 5 mg (GBX5)
Number of subjects: 794
Study 18853933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 794
Study 16087995 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/d of a mixed short and long degree of polymerization inulin-type fructan product (fructan group)
Number of subjects: 0
Study 16087995 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo (control group)
Number of subjects: 0
Study 12454760 — intervention group
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Number of subjects: 375
Study 12454760 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 375
Study 9036741 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin for ≤ 48 hours (group 1)
Number of subjects: 450
Study 9036741 — intervention group
Group type: COMPARATOR
Intervention: Heparin for > 48 hours (group 2)
Number of subjects: 450
Study 1677818 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.3 mg/kg for <10 kg, 0.5 mg/kg for >10 kg)
Number of subjects: 40
Study 1677818 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.05 mg/kg for <10 kg, 0.1 mg/kg for >10 kg)
Number of subjects: 40
Study 7011037 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement and 3% acyclovir ointment
Number of subjects: 50
Study 7011037 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir alone
Number of subjects: 50
Study 30689664 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r + RAL
Number of subjects: 126
Study 28903122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (Q2W)
Number of subjects: 3